Article
HHS peptide enforcement discretion policy, October 2026
On October 28, 2026, the Secretary of Health and Human Services filed an interim enforcement discretion policy saying HHS does not intend to take action against 503A pharmacies, federal facilities or licensed physicians compounding six peptides, BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, when ten conditions are met. The policy approves nothing, adds nothing to the 503A bulks list, binds nobody, and can be revisited if a safety signal appears. It prints in the Federal Register on October 30 as document 2026-22192.
Three months after the FDA's advisory committee voted for the six over its own scientists' objections, the department has stepped around the rulemaking that vote was supposed to feed. The policy is explicit that it is a stopgap: enforcement discretion "while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act is developed through rulemaking."
What it is, what it is not, and the ten conditions a pharmacy has to meet are below, with the primary document linked at each step. The conditions are where the work is for a prescriber, because a pharmacy that misses one is outside the policy.
What did HHS actually do?
The Department of Health and Human Services filed a notice of availability on the Federal Register public inspection desk on Wednesday, October 28, 2026, at 11:15 am Eastern. It prints in the Federal Register on Friday, October 30, as document 2026-22192, under docket HHS-OASH-2026-0496. The notice announces a document titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," signed by the Secretary, and points to a PDF on hhs.gov as the place the current version will be kept.
Three things about the filing matter before you read the policy itself. The issuing agency is the Office of the Secretary of HHS, not the FDA. The action is a notice of availability of an enforcement policy, not a rule, a proposed rule or a guidance for industry. And the notice itself says the policy "does not establish any rights for any person and is not binding on HHS or the public."
The policy's own words on what it does: "HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance" named in its Appendix A, while the FDA finishes the 503A bulks list through rulemaking, and only when every one of ten conditions is met.
Regulatory information from a licensed prescriber, not legal advice for your practice.
Which six peptides, and by which route?
Appendix A lists six substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. They are the six the Pharmacy Compounding Advisory Committee recommended in July 2026, over the objection of FDA staff. DSIP, which the committee voted against, is not on the list.
Appendix B is the part a pharmacy will live by. For each peptide it fixes the salt form, the amino acid sequence, the molecular formula and weight, and the dosage forms HHS considers appropriate. A product outside those identities is outside the policy.
| Substance (Appendix B identity) | Dosage forms named in Appendix B | HHS's stated reason for including it |
|---|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral and topical | Documented historical use, lot-specific certificates from an FDA registered facility, and the policy's own conditions |
| TB-500 acetate | Subcutaneous or intramuscular injection | Lot-specific certificates supply the results CDER found missing; CDER's safety concerns described as inferential rather than observed |
| Epitalon acetate | Subcutaneous or intramuscular injection, dispensed in intermittent courses | New lot data on endotoxin, microbial and solvent results; limited controlled human exposure reported no side effects |
| Semax (free base) | Intranasal | Certificates supply the endotoxin result CDER called the principal deficiency; an intranasal human record of several hundred subjects |
| KPV acetate | Topical and oral | Documented single-ingredient use; mass spectrometry confirmation of the active moiety on lots supplied to 503A pharmacies |
| MOTS-c acetate | Subcutaneous or intramuscular injection | Lot-specific certificates on impurity, solvent, endotoxin and microbial results; a placebo-controlled trial of an analogue with no serious adverse events |
Read the route column twice. BPC-157 is the only one of the six HHS names for oral and topical use alongside injection. KPV is topical and oral only, with no injectable form named. Semax is intranasal only. A compounder that makes an injectable KPV or an oral TB-500 is not inside the policy, whatever the pharmacy's website says.
Each Appendix B entry also records that the substance sat in the FDA's Category 2 from September 2023 until April 22, 2026, that "neither the placement nor the removal changed their status under section 503A," and that CDER recommended against listing. HHS is overriding its own drug center's scientific recommendation and says so in writing. The FDA's Category 1 list is unchanged. The 503A bulks list in 21 CFR 216.23 is unchanged.
What are the ten conditions?
The policy applies only when all ten conditions below are present. They are paraphrased from the policy; the numbering is HHS's.
- Interim access list. The peptide is in Appendix A.
- Identity. It has the identity and route limits in Appendix B, including sequence, structure, molecular weight and formula.
- Characterization. The bulk substance comes from a facility registered under section 510 with a certificate of analysis whose test results meet the testing standard in Appendix B: identity, purity, potency, and the absence of endotoxins, heavy metals, microbial contamination and impurities.
- The original manufacturer, not a repacker or distributor, is FDA registered, in compliance with current good manufacturing practice, and its physical location is on the certificate. A repacker or reseller must have validated the manufacturer and its certificate and documented that.
- Reporting. The compounder reports products compounded, serious adverse events and product quality issues to FDA's MedWatch and to the states where the product is compounded and sent. Product reporting names the active ingredient and strength, the original manufacturer with its facility identifier, and the dosage form and route. The patient labeling tells the patient how to report.
- Labeling. The label says: "This is a compounded drug product. Not for resale."
- One active ingredient. The product contains a single active pharmaceutical ingredient from Appendix A. Blends are outside the policy.
- Route. For an oral form, the compounder keeps documentation that the specific formulation achieves adequate oral bioavailability in humans.
- Device. The only delivery device co-packaged is an FDA 510(k) cleared syringe. No pens, no more complex devices.
- Everything else in the FD&C Act still applies, including the ban on insanitary conditions and 503A's patient-specific prescription requirement.
Condition 5 is the one that changes a prescriber's week. 503A compounders have never been required to report adverse events to the FDA, which the FDA's own staff pointed out at the July meeting when it cautioned that "no FAERS reports" does not mean safe. Under this policy, a pharmacy that wants the protection has to report. If your pharmacy cannot show you its reporting procedure and its manufacturer's certificate, it is not operating inside the policy.
What does the policy not do?
It does not approve anything. All six peptides remain unapproved drugs. The FDA has not reviewed their safety, effectiveness or quality.
It does not add anything to the 503A bulks list. The FDA's rulemaking continues, and the policy says FDA's future rulemakings "may propose adding some or all of these peptides" based on the evidence. It may also propose adding none.
It does not bind HHS. The policy can be revisited "in whole or in part," and the trigger HHS names is "a safety signal or product quality issue." The reporting it requires in condition 5 is how such a signal would reach the agency.
It does not cover 503B outsourcing facilities. The policy names state-licensed pharmacies, federal facilities and licensed physicians, the 503A universe. It does not cover any peptide outside Appendix A, any salt form or route outside Appendix B, any blend, or any research-use-only product. HHS's stated purpose is to pull patients away from exactly those products.
It does not change state law. State medical and pharmacy boards set their own rules on what a licensee may compound, prescribe or administer. The Alabama Board of Medical Examiners' 2026 action, and the other state actions on the peptide rules pages, stand as written until those boards say otherwise.
It does not settle the evidence. Nothing in the policy adds a controlled human trial to the record. The human evidence for the six peptides is what it was in July.
How do I comment, and when does it print?
The notice is scheduled to print in the Federal Register on October 30, 2026, at federalregister.gov/d/2026-22192. Written comments go to docket HHS-OASH-2026-0496 on regulations.gov and can be submitted until two weeks after the publication date. The contact named in the notice is Victoria Marshall at the Office of the Assistant Secretary for Health.
Comments matter here more than usual. The policy says HHS believes public comments "may provide additional evidence that FDA can consider in rulemaking." If you have controlled human data, adverse event experience or quality findings on any of the six, the docket is where it reaches the people writing the rule.
What should a prescriber do this week?
Ask your compounding pharmacy four questions, and write the answers in the chart. Is the product a single Appendix A peptide in its Appendix B salt form and route? Who is the original manufacturer, and can you see the certificate of analysis with the facility address on it? What is the pharmacy's procedure for reporting adverse events to MedWatch and the state? Does the label carry the required statement?
Keep documenting the evidence the way you did before October 28. A federal enforcement choice is not a change in what the studies show, and it is not a defense if a state board asks why a peptide was prescribed. The policy itself sends every unanswered question back to the clinician's judgment and the state's rules.
Frequently asked questions
Did HHS approve BPC-157, TB-500 or the other four peptides on October 28, 2026?
No. HHS said it does not intend to take enforcement action against 503A compounding of the six peptides under ten conditions, while the FDA keeps working on the 503A bulks list through rulemaking. None of the six is FDA approved and none was added to the 503A bulks list.
Which peptides does the HHS enforcement discretion policy cover?
Appendix A names six: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Appendix B fixes the identity, salt form and route for each one.
Is the HHS peptide policy binding, and can it be withdrawn?
No. The Federal Register notice says the policy establishes no rights and is not binding on HHS or the public. HHS says it may revisit the policy in whole or in part if a safety signal or a product quality issue arises.
What does a 503A pharmacy have to do under the HHS peptide policy?
Use only a peptide in Appendix A with the identity and route in Appendix B, from an FDA registered manufacturer with a certificate of analysis meeting the testing standard, keep to a single active ingredient, label the product as compounded and not for resale, report products, serious adverse events and quality problems to FDA and the states, and co-package only a 510(k) cleared syringe.
Where can I read the HHS peptide policy and comment on it?
The policy is a PDF on hhs.gov. The Federal Register notice is document 2026-22192, printed October 30, 2026, docket HHS-OASH-2026-0496. Written comments can be submitted on regulations.gov until two weeks after the publication date.
Does the HHS policy change what my state board allows?
No. It is a federal enforcement choice about the FD&C Act. State medical and pharmacy board rules, and the state actions on peptides taken in 2026, are unchanged by it.
How do you track the next move on peptides?
We update this page when the notice prints, when the comment period closes, when the FDA proposes a rule, and if HHS revises Appendix A or B. This policy was filed under the HHS agency on the Federal Register public inspection desk, a path our FDA focused monitoring did not watch. Since October 30, 2026 our monitoring reads that desk, the HHS news feed, and the policy PDF on hhs.gov every afternoon, and flags any filing or edit that names a peptide, compounding or the policy itself. The regulatory monitoring page shows what runs on a schedule today. This page is still updated by hand from the primary documents when something changes.
If your chart records the HHS policy but not the ten conditions it hangs on, book a short demo to see how Scriptura structures the evidence and the regulatory record for a peptide decision around the whole patient. Clinicians verify their license before platform access.
